Identification

Name
Mycophenolic acid
Accession Number
DB01024  (APRD01603, EXPT02208)
Type
Small Molecule
Groups
Approved
Description

Mycophenolic acid is an an immunosuppresant drug and potent anti-proliferative, and can be used in place of the older anti-proliferative azathioprine. It is usually used as part of triple therapy including a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. It is also useful in research for the selection of animal cells that express the E. coli gene coding for XGPRT (xanthine guanine phosphoribosyltransferase).

Structure
Thumb
Synonyms
  • (e)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid
  • Acide mycophenolique
  • Acido micofenolico
  • Acidum mycophenolicum
  • Micofenolico acido
  • Mycophenolate
  • Mycophenolsäure
External IDs
68618 / NSC-129185
Product Ingredients
IngredientUNIICASInChI Key
Mycophenolate sodiumWX877SQI1G37415-62-6DOZYTHNHLLSNIK-JOKMOOFLSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MyforticTablet, delayed release180 mg/1OralAvera Mc Kennan Hospital2015-03-012018-05-23Us
MyforticTablet, delayed release180 mg/1OralNovartis2004-02-27Not applicableUs
MyforticTablet, delayed release360 mgOralNovartis2005-02-11Not applicableCanada
MyforticTablet, delayed release180 mgOralNovartis2005-02-11Not applicableCanada
MyforticTablet, delayed release360 mg/1OralNovartis2004-02-27Not applicableUs00078 0386 66 nlmimage10 a116d0a6
Sandoz Mycophenolic AcidTablet, delayed release360 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz Mycophenolic AcidTablet, delayed release180 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-mycophenolic AcidTablet, delayed release180 mgOralApotex Corporation2014-07-02Not applicableCanada
Apo-mycophenolic AcidTablet, delayed release360 mgOralApotex Corporation2014-07-02Not applicableCanada
Mycophenolic AcidTablet, delayed release180 mg/1OralAmerincan Health Packaging2015-01-15Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralAccord Healthcare Limited2017-09-06Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralMylan Institutional2014-01-20Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralGolden State Medical Supply2014-10-13Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralMylan Pharmaceuticals2014-01-08Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralApotex Corporation2014-08-19Not applicableUs
Mycophenolic AcidTablet, delayed release180 mg/1OralMylan Institutional2014-01-20Not applicableUs
Mycophenolic AcidTablet, delayed release360 mg/1OralAccord Healthcare Limited2017-09-06Not applicableUs
International/Other Brands
Melbex
Categories
UNII
HU9DX48N0T
CAS number
24280-93-1
Weight
Average: 320.3371
Monoisotopic: 320.125988372
Chemical Formula
C17H20O6
InChI Key
HPNSFSBZBAHARI-RUDMXATFSA-N
InChI
InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+
IUPAC Name
(4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid
SMILES
COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C

Pharmacology

Indication

For the prophylaxis of organ rejection in patients receiving allogeneic renal transplants, administered in combination with cyclosporine and corticosteroids.

Associated Conditions
Pharmacodynamics

Mycophenolic acid is an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.

Mechanism of action

Mycophenolic acid is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Because T- and B-lymphocytes are critically dependent for their proliferation on de novo synthesis of purines, whereas other cell types can utilize salvage pathways, mycophenolic acid has potent cytostatic effects on lymphocytes. Mycophenolic acid inhibits proliferative responses of T- and B-lymphocytes to both mitogenic and allospecific stimulation. Addition of guanosine or deoxyguanosine reverses the cytostatic effects of mycophenolic acid on lymphocytes. Mycophenolic acid also suppresses antibody formation by B-lymphocytes. Mycophenolic acid prevents the glycosylation of lymphocyte and monocyte glycoproteins that are involved in intercellular adhesion to endothelial cells and may inhibit recruitment of leukocytes into sites of inflammation and graft rejection.

TargetActionsOrganism
AInosine-5'-monophosphate dehydrogenase 1
inhibitor
Human
AInosine-5'-monophosphate dehydrogenase 2
inhibitor
Human
Absorption

Bioavailability following oral administration of Myfortic delayed-release tablet ranges from 70-95%

Volume of distribution
  • 54 ± 25 L
Protein binding

>98%

Metabolism

Mycophenolic acid is metabolized mainly by glucuronyl transferase to glucuronidated metabolites, predominantly the phenolic glucuronide, mycophenolic acid glucuronide (MPAG). MPAG does not manifest pharmacological activity. The acyl glucuronide minor metabolite has pharmacological activity similar to mycophenolic acid. The AUC ratio of Mycophenolic acid:MPAG:acyl glucuronide is approximately 1:24:0.28 at steady state.

Route of elimination
Not Available
Half life

The mean elimination half-life for mycophenolic acid ranges from 8-16 hours, while that of the MPAG metabolite ranges from 13-17 hours.

Clearance
  • 140 +/- 30 mL/min [Stable renal transplant patients]
Toxicity

Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg Rabbit. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Mycophenolic Acid Metabolism PathwayDrug metabolism
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with 5-androstenedione.Experimental, Illicit
AbciximabMycophenolic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololMycophenolic acid may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolMycophenolic acid may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved
AcetyldigoxinAcetyldigoxin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Mycophenolic acid.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aldosterone.Experimental, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alendronic acid.Approved
AliskirenMycophenolic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlmasilateAlmasilate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
AlminoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Alminoprofen.Experimental
AloglutamolAloglutamol can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AlprenololMycophenolic acid may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
AluminiumAluminium can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Aluminium acetoacetateAluminium acetoacetate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminium glycinateAluminium glycinate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Amcinonide.Approved
AmdinocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amdinocillin resulting in a loss in efficacy.Investigational, Withdrawn
AmilorideMycophenolic acid may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aminosalicylic Acid.Approved
AmoxicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Amoxicillin resulting in a loss in efficacy.Approved, Vet Approved
AmpicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ampicillin resulting in a loss in efficacy.Approved, Vet Approved
AncestimThe risk or severity of cytotoxicity can be increased when Ancestim is combined with Mycophenolic acid.Approved, Investigational, Withdrawn
AncrodMycophenolic acid may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anisodamine.Investigational
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Anthrax immune globulin human.Approved
AntipyrineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antipyrine.Approved, Investigational
Antithrombin III humanMycophenolic acid may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Antrafenine.Approved
ApixabanMycophenolic acid may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apocynin.Investigational
ApramycinMycophenolic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Apremilast.Approved, Investigational
ArbekacinMycophenolic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMycophenolic acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMycophenolic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololMycophenolic acid may decrease the antihypertensive activities of Arotinolol.Investigational
AsenapineMycophenolic acid may decrease the antihypertensive activities of Asenapine.Approved
AspoxicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Aspoxicillin resulting in a loss in efficacy.Experimental
AtamestaneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Atamestane.Investigational
AtenololMycophenolic acid may decrease the antihypertensive activities of Atenolol.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Mycophenolic acid.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Azficel-T.Approved, Investigational
AzidocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azidocillin resulting in a loss in efficacy.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Mycophenolic acid.Approved, Investigational
AzlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Azlocillin resulting in a loss in efficacy.Approved
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Mycophenolic acid.Investigational
BacampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Bacampicillin resulting in a loss in efficacy.Approved, Investigational
Bacillus calmette-guerin substrain connaught live antigenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bacillus calmette-guerin substrain connaught live antigen.Approved, Investigational
Bacillus calmette-guerin substrain tice live antigenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bacillus calmette-guerin substrain tice live antigen.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Balsalazide.Approved, Investigational
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Mycophenolic acid.Investigational
BecaplerminMycophenolic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMycophenolic acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMycophenolic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BenazeprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benazepril.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved
BenorilateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benoxaprofen.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Mycophenolic acid.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Benzydamine.Approved
BenzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
Benzylpenicilloyl PolylysineThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Benzylpenicilloyl Polylysine resulting in a loss in efficacy.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Mycophenolic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololMycophenolic acid may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Mycophenolic acid.Approved, Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
BevantololMycophenolic acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bevonium.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
Bismuth subcitrate potassiumBismuth Subcitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Bismuth subnitrateBismuth subnitrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololMycophenolic acid may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMycophenolic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololMycophenolic acid may decrease the antihypertensive activities of Bopindolol.Approved
BromfenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bucillamine.Investigational
BucindololMycophenolic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bufexamac.Approved, Experimental
BufuralolMycophenolic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Mycophenolic acid.Approved
BupranololMycophenolic acid may decrease the antihypertensive activities of Bupranolol.Approved
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Mycophenolic acid.Approved
Calcium CarbonateCalcium Carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Calcium silicateCalcium silicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Mycophenolic acid.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Mycophenolic acid.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Candoxatril.Experimental
CapsaicinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Captopril.Approved
CarbamazepineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Carbaspirin calcium.Experimental, Investigational
CarbenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carbenicillin resulting in a loss in efficacy.Approved, Investigational
Carbenicillin indanylThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carbenicillin indanyl resulting in a loss in efficacy.Approved, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved
CarfecillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Carfecillin resulting in a loss in efficacy.Experimental
CarprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMycophenolic acid may decrease the antihypertensive activities of Carteolol.Approved
CastanospermineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Castanospermine.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Celecoxib.Approved, Investigational
CeliprololMycophenolic acid may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMycophenolic acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlormadinoneThe serum concentration of Chlormadinone can be decreased when it is combined with Mycophenolic acid.Experimental
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Mycophenolic acid.Approved
CholestyramineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cholestyramine.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cimicoxib.Investigational
CinoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cisplatin.Approved
ClobetasolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonixinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Mycophenolic acid.Vet Approved
CloranololMycophenolic acid may decrease the antihypertensive activities of Cloranolol.Experimental
Clostridium tetani toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).Approved
CloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cloxacillin resulting in a loss in efficacy.Approved, Investigational, Vet Approved
ColesevelamThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Mycophenolic acid can be decreased when it is combined with Colestipol.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Cortisone acetate.Approved, Investigational
Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated).Approved
CurcuminThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Curcumin.Approved, Investigational
CyclacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Cyclacillin resulting in a loss in efficacy.Approved
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Mycophenolic acid.Experimental
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
CyclosporineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinCymarin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
Cyproterone acetateThe serum concentration of Cyproterone acetate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
Dabigatran etexilateMycophenolic acid may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinMycophenolic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMycophenolic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMycophenolic acid may increase the anticoagulant activities of Darexaban.Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Delapril.Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Mycophenolic acid.Approved
DesipramineMycophenolic acid may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinMycophenolic acid may increase the anticoagulant activities of Desirudin.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Mycophenolic acid.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desmopressin.Approved
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Mycophenolic acid.Approved
DesonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Mycophenolic acid.Approved, Investigational
DexlansoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Dexlansoprazole.Approved, Investigational
DexrabeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Dexrabeprazole.Experimental
DextranMycophenolic acid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinMycophenolic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Dibotermin alfa.Approved, Investigational
DicloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Dicloxacillin resulting in a loss in efficacy.Approved, Investigational, Vet Approved
DicoumarolMycophenolic acid may increase the anticoagulant activities of Dicoumarol.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Mycophenolic acid.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
DifenpiramideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Difluprednate.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mycophenolic acid.Approved
Digoxin Immune Fab (Ovine)Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Mycophenolic acid.Approved
DihydrostreptomycinMycophenolic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Mycophenolic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Mycophenolic acid.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid.Approved, Investigational
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Mycophenolic acid.Approved
DroxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with E-6201.Investigational
Edetic AcidMycophenolic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMycophenolic acid may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalaprilat.Approved
EnoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Enoxacin.Approved, Investigational
EnoxaparinMycophenolic acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Mycophenolic acid.Experimental
EpanololMycophenolic acid may decrease the antihypertensive activities of Epanolol.Experimental
EpicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Epicillin resulting in a loss in efficacy.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Epirizole.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Mycophenolic acid.Experimental
EplerenoneMycophenolic acid may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Mycophenolic acid.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Mycophenolic acid.Approved
EquileninThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Equilin.Approved
EsatenololMycophenolic acid may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololMycophenolic acid may decrease the antihypertensive activities of Esmolol.Approved
EsomeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Esomeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Mycophenolic acid.Approved, Investigational, Vet Approved
Estradiol cypionateThe serum concentration of Estradiol cypionate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational, Vet Approved
Estradiol valerateThe serum concentration of Estradiol valerate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational, Vet Approved
EstroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ethenzamide.Experimental
Ethyl biscoumacetateMycophenolic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Mycophenolic acid.Approved
Etidronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etofenamate.Approved, Investigational
EtonogestrelThe serum concentration of Etonogestrel can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Evening primrose oil.Investigational, Nutraceutical
EverolimusThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Everolimus.Approved
ExisulindThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Mycophenolic acid.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Feprazone.Experimental
Ferulic acidMycophenolic acid may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Mycophenolic acid.Approved, Investigational
FingolimodMycophenolic acid may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FleroxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Mycophenolic acid.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluasterone.Investigational
FlucloxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Flucloxacillin resulting in a loss in efficacy.Approved, Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fludrocortisone.Approved, Investigational
FluindioneMycophenolic acid may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Mycophenolic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Mycophenolic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxMycophenolic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Mycophenolic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Formestane.Approved, Investigational, Withdrawn
FramycetinMycophenolic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
G17DTThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with G17DT.Investigational
GabexateMycophenolic acid may increase the anticoagulant activities of Gabexate.Investigational
GanciclovirThe serum concentration of Ganciclovir can be increased when it is combined with Mycophenolic acid.Approved, Investigational
GarenoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Garenoxacin.Investigational
GatifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Gemcitabine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Mycophenolic acid.Approved, Withdrawn
GemifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Gemifloxacin.Approved, Investigational
GeneticinMycophenolic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMycophenolic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMycophenolic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
GestrinoneThe serum concentration of Gestrinone can be decreased when it is combined with Mycophenolic acid.Approved
GI-5005The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with GI-5005.Investigational
GinsengThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ginseng.Approved, Investigational, Nutraceutical
GitoformateGitoformate may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
GrepafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with HE3286.Investigational
HeparinMycophenolic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
Hepatitis A VaccineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hepatitis A Vaccine.Approved
Hepatitis B Vaccine (Recombinant)The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hepatitis B Vaccine (Recombinant).Approved, Withdrawn
HigenamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Higenamine.Investigational
Human rabies virus immune globulinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Human rabies virus immune globulin.Approved
HydralazineMycophenolic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone.Approved, Vet Approved
Hydrocortisone acetateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone acetate.Approved, Vet Approved
Hydrocortisone butyrateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Hydrocortisone butyrate.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
HydrotalciteHydrotalcite can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental, Investigational
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
Hygromycin BMycophenolic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbuproxamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Icosapent.Approved, Nutraceutical
IdraparinuxMycophenolic acid may increase the anticoagulant activities of Idraparinux.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Mycophenolic acid.Approved
IndenololMycophenolic acid may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Indoprofen.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with INGN 225.Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Mycophenolic acid.Approved, Investigational
IrinotecanThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Irinotecan.Approved, Investigational
IsavuconazoniumThe serum concentration of Mycophenolic acid can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsepamicinMycophenolic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Istaroxime.Investigational
Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated)The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated).Approved
KanamycinMycophenolic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ketoprofen.Approved, Vet Approved
LamotrigineThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lamotrigine.Approved, Investigational
Lanatoside CLanatoside C may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
LandiololMycophenolic acid may decrease the antihypertensive activities of Landiolol.Investigational
LansoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Leflunomide.Approved, Investigational
LepirudinMycophenolic acid may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMycophenolic acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololMycophenolic acid may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololMycophenolic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.Approved, Investigational
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lisofylline.Investigational
Lithium cationThe serum concentration of Lithium can be increased when it is combined with Mycophenolic acid.Experimental
LomefloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Lomefloxacin.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lornoxicam.Approved, Investigational
LoteprednolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Mycophenolic acid.Vet Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
MagaldrateMagaldrate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Magnesium hydroxideThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium hydroxide.Approved, Investigational
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium peroxideMagnesium peroxide can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Magnesium salicylateThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium salicylate.Approved
Magnesium silicateMagnesium silicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium sulfateThe serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Mycophenolic acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with ME-609.Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Meclofenamic acid.Approved, Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mefenamic acid.Approved
Megestrol acetateThe serum concentration of Megestrol acetate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational, Vet Approved
MelagatranMycophenolic acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Meloxicam.Approved, Vet Approved
MepindololMycophenolic acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mesalazine.Approved
MestranolThe serum concentration of Mestranol can be decreased when it is combined with Mycophenolic acid.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.Approved, Investigational, Withdrawn
MetampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Metampicillin resulting in a loss in efficacy.Experimental
MethimazoleThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methimazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Methylprednisolone.Approved, Vet Approved
MeticillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Meticillin resulting in a loss in efficacy.Approved, Investigational
MetildigoxinMetildigoxin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
MetipranololMycophenolic acid may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Mycophenolic acid.Approved
MetronidazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole.Approved
MezlocillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Mezlocillin resulting in a loss in efficacy.Approved, Investigational
MicronomicinMycophenolic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mycophenolic acid.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Mycophenolic acid.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Mycophenolic acid.Approved
MoxifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Mycophenolic acid.Approved, Investigational
NabumetoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nabumetone.Approved
NadololMycophenolic acid may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMycophenolic acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatMycophenolic acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NafcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Nafcillin resulting in a loss in efficacy.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Mycophenolic acid.Approved
Nalidixic AcidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Nalidixic Acid.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.Approved, Investigational
NCX 1022The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with NCX 1022.Investigational
NeamineMycophenolic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololMycophenolic acid may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NemonoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Nemonoxacin.Investigational
NepafenacThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nepafenac.Approved, Investigational
NetilmicinMycophenolic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Niflumic Acid.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Nitroaspirin.Investigational
Nomegestrol acetateThe serum concentration of Nomegestrol acetate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Mycophenolic acid.Approved
NorethynodrelThe serum concentration of Norethynodrel can be decreased when it is combined with Mycophenolic acid.Approved
NorfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Norfloxacin.Approved
NorgestimateThe serum concentration of Norgestimate can be decreased when it is combined with Mycophenolic acid.Approved, Investigational
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Mycophenolic acid.Approved
NorgestrienoneThe serum concentration of Norgestrienone can be decreased when it is combined with Mycophenolic acid.Experimental
OcrelizumabOcrelizumab may increase the immunosuppressive activities of Mycophenolic acid.Approved, Investigational
OfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Ofloxacin.Approved
OleandrinOleandrin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental, Investigational
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Mycophenolic acid.Approved
OlsalazineMycophenolic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Mycophenolic acid is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Omapatrilat.Investigational
OmeprazoleOmeprazole can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
OrgoteinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Orgotein.Vet Approved
OtamixabanMycophenolic acid may increase the anticoagulant activities of Otamixaban.Investigational
OuabainOuabain may decrease the cardiotoxic activities of Mycophenolic acid.Approved
OxacillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Oxacillin resulting in a loss in efficacy.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxaprozin.Approved
Oxolinic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Oxolinic acid.Experimental
OxprenololMycophenolic acid may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Mycophenolic acid.Approved, Vet Approved
PalmidrolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pamidronate.Approved
PantoprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pantoprazole.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parecoxib.Approved
ParthenolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Parthenolide.Approved, Investigational
PazufloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pazufloxacin.Investigational
PefloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pefloxacin.Approved
PenamecillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Penamecillin resulting in a loss in efficacy.Experimental
PenbutololMycophenolic acid may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateMycophenolic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateMycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Perindopril.Approved
PeruvosidePeruvoside may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
PhenindioneMycophenolic acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe serum concentration of Mycophenolic acid can be decreased when it is combined with Phenobarbital.Approved, Investigational
PhenoxymethylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Phenoxymethylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
PhenprocoumonMycophenolic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Mycophenolic acid.Approved, Investigational
PindololMycophenolic acid may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Pipemidic acid.Experimental
PiperacillinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Piperacillin.Approved
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Mycophenolic acid.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirfenidone.Approved, Investigational
Piromidic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pitolisant.Approved, Investigational
PivampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivampicillin resulting in a loss in efficacy.Approved
PivmecillinamThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Pivmecillinam resulting in a loss in efficacy.Approved
Platelet Activating FactorMycophenolic acid may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinMycophenolic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Approved, Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Mycophenolic acid.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pomalidomide.Approved
Potassium CitrateMycophenolic acid may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololMycophenolic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Mycophenolic acid.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Mycophenolic acid can be increased when it is combined with Probenecid.Approved, Investigational
Procaine benzylpenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Procaine benzylpenicillin resulting in a loss in efficacy.Approved, Vet Approved
ProglumetacinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Propacetamol.Approved, Investigational
PropicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Propicillin resulting in a loss in efficacy.Experimental
PropyphenazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Proquazone.Experimental
ProscillaridinProscillaridin may decrease the cardiotoxic activities of Mycophenolic acid.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Mycophenolic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Mycophenolic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Mycophenolic acid.Vet Approved
Protein CMycophenolic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanMycophenolic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMycophenolic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with PTC299.Investigational
PuromycinMycophenolic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Mycophenolic acid.Approved
QuingestanolThe serum concentration of Quingestanol can be decreased when it is combined with Mycophenolic acid.Experimental
RabeprazoleThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rabeprazole.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rabies virus inactivated antigen, A.Approved, Investigational
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinMycophenolic acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMycophenolic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rimexolone.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rindopepimut.Investigational
RisedronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Risedronate.Approved, Investigational
RivaroxabanMycophenolic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rofecoxib.Approved, Investigational, Withdrawn
RoflumilastRoflumilast may increase the immunosuppressive activities of Mycophenolic acid.Approved
RosoxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rosoxacin.Approved, Investigational
Rotavirus VaccineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rotavirus Vaccine.Approved
Rubella virus vaccineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Rubella virus vaccine.Approved, Investigational
RufloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Rufloxacin.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Mycophenolic acid.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salicylamide.Approved
Salmonella typhi ty2 vi polysaccharide antigenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salmonella typhi ty2 vi polysaccharide antigen.Approved
Salmonella typhi Ty21a live antigenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salmonella typhi ty21a live antigen.Approved
SalsalateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Mycophenolic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Mycophenolic acid.Investigational
SeliciclibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Serrapeptase.Investigational
SevelamerThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sevelamer.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
SisomicinMycophenolic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sitafloxacin.Experimental, Investigational
Sodium bicarbonateSodium bicarbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
SotalolMycophenolic acid may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Spirapril.Approved
SRP 299The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with SRT501.Investigational
StreptomycinMycophenolic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
SulbenicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sulbenicillin resulting in a loss in efficacy.Experimental
SulfasalazineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Sulfasalazine.Approved
SulodexideMycophenolic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Mycophenolic acid.Investigational
SultamicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Sultamicillin resulting in a loss in efficacy.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Suxibuzone.Experimental
TacrolimusTacrolimus may increase the immunosuppressive activities of Mycophenolic acid.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Mycophenolic acid.Approved
TalampicillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Talampicillin resulting in a loss in efficacy.Experimental
TalinololMycophenolic acid may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Mycophenolic acid.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Mycophenolic acid.Approved
TecemotideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tecemotide.Investigational
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Mycophenolic acid.Approved, Investigational
TemafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Temocapril.Experimental, Investigational
TenidapThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenidap.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tepoxalin.Vet Approved
TerbutalineMycophenolic acid may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide.Approved
TertatololMycophenolic acid may decrease the antihypertensive activities of Tertatolol.Experimental
TetrandrineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tetrandrine.Experimental
TG4010The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with TG4010.Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiaprofenic acid.Approved
TicarcillinThe serum concentration of the active metabolites of Mycophenolic acid can be reduced when Mycophenolic acid is used in combination with Ticarcillin resulting in a loss in efficacy.Approved, Investigational, Vet Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololMycophenolic acid may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tinoridine.Investigational
TixocortolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tixocortol.Approved, Withdrawn
TobramycinMycophenolic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibMycophenolic acid may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tolmetin.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Mycophenolic acid.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Trandolapril.Approved
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Mycophenolic acid.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Mycophenolic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Mycophenolic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMycophenolic acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Mycophenolic acid.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Triptolide.Investigational
TromethamineTromethamine can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TrovafloxacinThe serum concentration of Mycophenolic acid can be decreased when it is combined with Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinMycophenolic acid may increase the anticoagulant activities of Troxerutin.Investigational
Typhoid VaccineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Typhoid Vaccine.Approved
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Mycophenolic acid.Approved
UlobetasolThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Mycophenolic acid.Approved, Investigational
ValaciclovirThe serum concentration of Mycophenolic acid can be increased when it is combined with Valaciclovir.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValganciclovirThe serum concentration of Valganciclovir can be increased when it is combined with Mycophenolic acid.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Mycophenolic acid.Approved, Investigational
Varicella Zoster Vaccine (Live/Attenuated)The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Varicella Zoster Vaccine (Live/Attenuated).Approved
WarfarinMycophenolic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMycophenolic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Yellow Fever VaccineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Yellow Fever Vaccine.Approved, Investigational
ZaltoprofenThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zidovudine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Mycophenolic acid.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zofenopril.Experimental
ZomepiracThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

Synthesis Reference

Bernard J. Abbott, John G. Whitney, "Method of preparing mycophenolic acid glucoside." U.S. Patent US4234684, issued January, 1976.

US4234684
General References
  1. Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS: Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study. Health Technol Assess. 2005 May;9(21):1-179, iii-iv. [PubMed:15899149]
External Links
Human Metabolome Database
HMDB0015159
PubChem Compound
446541
PubChem Substance
46504559
ChemSpider
393865
BindingDB
19264
ChEBI
168396
ChEMBL
CHEMBL866
Therapeutic Targets Database
DAP000784
PharmGKB
PA164748728
HET
MOA
Drugs.com
Drugs.com Drug Page
Wikipedia
Mycophenolic_acid
ATC Codes
L04AA06 — Mycophenolic acid
AHFS Codes
  • 92:44.00 — Immunosuppressive Agents
PDB Entries
1jr1 / 1me7 / 1meh / 1mei / 4af0 / 4fo4 / 4fxs
MSDS
Download (74 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0TerminatedTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
0WithdrawnTreatmentMultiple Myeloma (MM) / Myeloma-Multiple1
1CompletedTreatmentDrug Interaction Potentiation1
1CompletedTreatmentEnd Stage Renal Disease (ESRD) / Transplantation, Kidney1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPrimary Sjogren's Syndrome1
1RecruitingTreatmentAgnogenic Myeloid Metaplasia / Leukemias / Malignant Lymphomas / Smith-Magenis Syndrome1
1RecruitingTreatmentHaemoglobinopathies congenital / Sickle Cell Disorders / Thalassaemic disorders1
1RecruitingTreatmentRenal Transplanted Recipients / Transplantation, Kidney / Transplantation, Renal1
1RecruitingTreatmentTransplantation, Liver1
1, 2CompletedBasic ScienceTransplantation, Kidney1
1, 2CompletedTreatmentDiabetes, Diabetes Mellitus Type 11
1, 2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignancies, Hematologic1
1, 2CompletedTreatmentMalignancies, Hematologic1
1, 2CompletedTreatmentScleroderma, Systemic / Severe Systemic Sclerosis1
1, 2CompletedTreatmentTransplantation, Kidney1
1, 2RecruitingTreatmentAdult Living Donor Kidney Transplant Recipients / Living Kidney Donors / Transplant, Kidney1
1, 2Unknown StatusTreatmentHematologic Diseases1
2Active Not RecruitingPreventionGraft Versus Host Disease (GVHD)1
2Active Not RecruitingTreatmentLeukemias / Malignant Lymphomas1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentNephritis, Lupus1
2CompletedTreatmentTransplantation, Renal1
2Not Yet RecruitingTreatmentAntibody-mediated Rejection / Lung Transplant Rejection1
2RecruitingTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Acute, secondary Myeloid Leukemia / Adult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Chronic Myelogenous Leukemia / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Myelodysplastic Syndromes / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Chronic Myelomonocytic Leukemia / Chronic Phase Chronic Myelogenous Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Juvenile Myelomonocytic Leukemia / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Polycythemia Vera (PV) / Post-Transplant Lymphoproliferative Disorder / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Cytopenia With Multilineage Dysplasia / Refractory Hairy Cell Leukemia / Refractory Multiple Myeloma / Relapsing Chronic Myelogenous Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenström's Macroglobulinemia (WM)1
2RecruitingTreatmentAcute myeloid leukaemia (in remission) / Aplastic Anaemia (AA) / Chronic Myelomonocytic Leukemia / Indolent Non-Hodgkin's Lymphomas / Leukemia Acute Myeloid Leukemia (AML) / Lymphoma, Hodgkins / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Neoplasms, Malignant / Plasma Cell Myeloma / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Ring Sideroblasts / Refractory Cytopenia With Multilineage Dysplasia / Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts1
2RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2SuspendedTreatmentCrohn's Disease (CD)1
2TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / All / Chronic Lymphocytic Leukaemia (CLL) / CLL / Leukemia Acute Myeloid Leukemia (AML) / Leukemias / Lymphoma, Hodgkins / Malignancies, Hematologic / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL) / Plasma Cell Myeloma1
2TerminatedTreatmentLeukemias / Myelodysplastic Syndromes1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentNeoplasms, Malignant1
2Unknown StatusTreatmentRenal Insufficiency,Chronic / Transplantation, Liver1
2WithdrawnTreatmentDiabetes, Diabetes Mellitus Type 11
2, 3RecruitingTreatmentLeukemia Acute Myeloid Leukemia (AML)1
3Active Not RecruitingTreatmentUveitis, Intermediate1
3CompletedPreventionTransplantation, Kidney1
3CompletedTreatmentAutoimmune Diseases1
3CompletedTreatmentGlomerulonephritis minimal lesion1
3CompletedTreatmentKidney Diseases1
3CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
3CompletedTreatmentPancreas Transplantation / Transplantation, Kidney1
3CompletedTreatmentRejection, Transplant / Transplantation, Kidney1
3CompletedTreatmentRenal Interstitial Fibrosis1
3CompletedTreatmentTransplant, Kidney4
3CompletedTreatmentTransplant; Failure, Kidney1
3CompletedTreatmentTransplantation, Kidney2
3CompletedTreatmentTransplantation, Liver3
3CompletedTreatmentTransplantation, Renal3
3RecruitingTreatmentChronic Kidney Disease (CKD)1
3TerminatedNot AvailableSarcoidosis, Pulmonary1
3TerminatedTreatmentGraft Versus Host Disease (GVHD)1
3TerminatedTreatmentNephritis, Lupus1
3TerminatedTreatmentSystemic Lupus Erythematosus (SLE)1
3Unknown StatusTreatmentHeart Transplant Patients1
4Active Not RecruitingPreventionInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentCytomegalovirus / Transplantation, Kidney1
4Active Not RecruitingTreatmentInfections, Cytomegalovirus / Transplantation Infection1
4Active Not RecruitingTreatmentKidney Transplant Rejection / Other Complications of Kidney Transplant1
4Active Not RecruitingTreatmentTransplantation, Renal1
4CompletedPreventionAdverse Effects / Transplantation, Kidney1
4CompletedPreventionHepatitis C Viral Infection1
4CompletedPreventionTransplantation, Kidney1
4CompletedSupportive CareTransplantation, Renal1
4CompletedTreatmentBK Virus Infection1
4CompletedTreatmentBioavailability / Concomitant Medication After Renal Transplantation / Drug Interactions / Immunosuppressive Medication After Renal Transplantation1
4CompletedTreatmentChronic Kidney Disease (CKD) / End Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Renal Replacement Therapies / Transplantation, Renal1
4CompletedTreatmentChronic Renal Failure (CRF)1
4CompletedTreatmentDisorder Related to Renal Transplantation / Infections, Cytomegalovirus1
4CompletedTreatmentEnd Stage Renal Disease (ESRD)1
4CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
4CompletedTreatmentGastrointestinal Lesions / Signs and Symptoms, Digestive1
4CompletedTreatmentGastrointestinal Problems / Transplantation, Renal1
4CompletedTreatmentGastrointestinal Symptoms / Heart Transplantation1
4CompletedTreatmentGlomerulonephritis minimal lesion1
4CompletedTreatmentHeart Transplantation1
4CompletedTreatmentImplant or Graft; Rejection1
4CompletedTreatmentInfections, Cytomegalovirus / Renal Transplant Failure / Transplant; Complication, Rejection1
4CompletedTreatmentKidney Transplant Recipients1
4CompletedTreatmentLiver Cirrhosis / Liver Transplant Disorder1
4CompletedTreatmentRenal Function1
4CompletedTreatmentRenal Transplanted Recipients1
4CompletedTreatmentTransplant, Kidney2
4CompletedTreatmentTransplant, Kidney / Transplantation, Kidney1
4CompletedTreatmentTransplantation, Kidney2
4CompletedTreatmentTransplantation, Liver1
4CompletedTreatmentTransplantation, Renal3
4Not Yet RecruitingTreatmentImmunosuppression After Renal Transplantation / Transplant, Kidney1
4RecruitingPreventionInfections, Cytomegalovirus1
4RecruitingPreventionKidney Transplant Infection1
4RecruitingTreatmentAntibody Mediated Rejection / End Stage Renal Disease (ESRD)1
4RecruitingTreatmentChronic Renal Failure (CRF) / Graft Failure / Kidney Transplant Rejection / Transplant; Failure, Kidney1
4RecruitingTreatmentGastrointestinal Disorder, Functional / Kidney Transplant Rejection1
4RecruitingTreatmentHepatocellular,Carcinoma1
4RecruitingTreatmentImmunosuppression1
4TerminatedPreventionSkin Cancers / Transplantation, Kidney1
4TerminatedPreventionTransplantation, Kidney1
4TerminatedPreventionTransplantation, Renal1
4TerminatedTreatmentTransplantation, Kidney / Transplants and Implants1
4TerminatedTreatmentTransplantation, Renal2
4Unknown StatusPreventionDiabetes Mellitus (DM) / Rejection, Transplant1
4Unknown StatusPreventionKidney; Complications, Allograft1
4Unknown StatusTreatmentInfections, Cytomegalovirus1
4Unknown StatusTreatmentTransplant, Kidney1
4Unknown StatusTreatmentTransplantation, Organ1
4Unknown StatusTreatmentTransplantation, Renal1
4WithdrawnTreatmentCardiovascular Disease (CVD) / Cardiovascular Outcomes / Kidney Transplant Recipients / Transplantation, Kidney1
4WithdrawnTreatmentLiving Donor Kidney Transplants Patients1
4WithdrawnTreatmentReperfusion Injury / Transplantation, Kidney / Transplantation, Renal1
4WithdrawnTreatmentTransplantation, Liver1
Not AvailableCompletedNot AvailableDiabetes, Diabetes Mellitus Type 1 / Islet Transplantation1
Not AvailableCompletedNot AvailableEnd Stage Liver Diseases1
Not AvailableCompletedNot AvailableGI Disturbance1
Not AvailableCompletedTreatmentArthritis / Systemic Lupus Erythematosus (SLE)1
Not AvailableCompletedTreatmentHigh Model for End-Stage Liver Disease (MELD) Score1
Not AvailableCompletedTreatmentImmunosuppression2
Not AvailableNo Longer AvailableNot AvailableDiabetes, Diabetes Mellitus Type 11
Not AvailableNot Yet RecruitingNot AvailableAcute Rejection of Renal Transplant / Biopsy Proven Acute Rejection (BPAR) / Bone Diseases / Cardiovascular Risk Factors / Graft Failure / HLA Antibody Production / Infection NOS / Mortality / Non-HLA Antibody Production / Post Transplant Diabetes Mellitus / Quality of Life1
Not AvailableRecruitingNot AvailableNephritis, Lupus1
Not AvailableRecruitingPreventionDiabetes, Diabetes Mellitus Type 11
Not AvailableRecruitingPreventionImmunosuppression / Renal Failure1
Not AvailableRecruitingTreatmentDisorder Related to Renal Transplantation / Effects of Immunosuppressant Therapy1
Not AvailableTerminatedTreatmentAcute Rejection / Transplantation, Renal1
Not AvailableTerminatedTreatmentTransplantation, Kidney1
Not AvailableTerminatedTreatmentTransplantation, Liver1
Not AvailableUnknown StatusNot AvailableUveitis1
Not AvailableUnknown StatusTreatmentMyasthenia Gravis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Novartis AG
Dosage forms
FormRouteStrength
Tablet, delayed releaseOral180 mg
Tablet, delayed releaseOral360 mg
Tablet, delayed releaseOral180 mg/1
Tablet, delayed releaseOral360 mg/1
Prices
Unit descriptionCostUnit
Myfortic 360 mg Enteric Coated Tabs8.0USD tab
Myfortic 360 mg tablet7.69USD tablet
Myfortic 180 mg tablet3.85USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2250906No2006-10-032017-04-10Canada
US6025391No1997-04-102017-04-10Us
US6172107No1997-04-102017-04-10Us
US6306900No1998-02-272018-02-27Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)141 °CPhysProp
water solubilityInsolubleNot Available
logP2.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0355 mg/mLALOGPS
logP2.36ALOGPS
logP3.53ChemAxon
logS-4ALOGPS
pKa (Strongest Acidic)3.57ChemAxon
pKa (Strongest Basic)-4.1ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area93.06 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity85.23 m3·mol-1ChemAxon
Polarizability32.95 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9409
Blood Brain Barrier+0.5826
Caco-2 permeable-0.5583
P-glycoprotein substrateSubstrate0.8058
P-glycoprotein inhibitor INon-inhibitor0.7888
P-glycoprotein inhibitor IIInhibitor0.545
Renal organic cation transporterNon-inhibitor0.8199
CYP450 2C9 substrateNon-substrate0.8305
CYP450 2D6 substrateNon-substrate0.8575
CYP450 3A4 substrateSubstrate0.6934
CYP450 1A2 substrateInhibitor0.9107
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9232
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7237
Ames testAMES toxic0.9107
CarcinogenicityNon-carcinogens0.9619
BiodegradationReady biodegradable0.5888
Rat acute toxicity2.9907 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.753
hERG inhibition (predictor II)Non-inhibitor0.6329
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0490000000-99420edc8894323b59c3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-b99d88ff2ddeb6977c4a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0149000000-ed6b854b4f9af495c8d8
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0972000000-12d0e80f109d1fa6eb11
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0950000000-2e6c3543fe3f9f4e0790
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0930000000-e7a74fbe76e7141ec5f3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-022c-0910000000-27f7c0023a8b7e5b4d66
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-4aba5ee4ba77899b36fb
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0149000000-497b49ab395f3319c943
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0971000000-68634f04b665bb0e68a3
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0006-0950000000-37f2ee0320d2ec560b93
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0f6x-0930000000-500359a3fd82c686ff99
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-006x-0900000000-6d04c3395aae26f88529
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0590000000-fe2f27357ba775714c5a
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-8f75c9bc48b5eb019974
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014i-0009000000-57a06531623d00c32d13
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0490000000-700501110e03f998e99b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002r-0490000000-d857a6e047fc52e09e65
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0659000000-ba96d820001d9e786c8d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-8855932a0a5c9af1f1f6
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-5eab5855829b8f8b0eea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-0093000000-19fd59af4878ea5f1a97
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0190000000-6f584505d9b70bbffa5e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0890000000-fb7dec2fc3d23163125f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1910000000-107f1e78387f32f7de88
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pbc-3900000000-b1724166cac37a86cf14
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-8de82df3dfe7724905cc
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pb9-0093000000-921ff4437b7ebfa1c724
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0190000000-51bdcbf497148c8b5520
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-0890000000-c295a83b84c00d94f85f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1910000000-92e91c6ef0f2c538121f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0pbc-3900000000-410eebeb0513756f40b0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0udi-0009000000-77bcd201c9d0349c0389
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-da3123e3ecb85f0d28ff
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-90103d288430929083b5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0090000000-3f6f29caf26c0469c12c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0uxr-0090000000-7fc1bdce2eebcc00617c
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0udi-0019000000-01d925bb1f9079308d85
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0091000000-22fc916594dbab851293
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0940000000-84f4c65c2cd8b7358b78
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0593000000-1fed07ad435ca0bd7249
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0950000000-87024d6b180d1fc1c64f
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0493000000-9b99fb030e87f52cce17
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-0294000000-31d6abb5cfcd65770f2c

Taxonomy

Description
This compound belongs to the class of organic compounds known as phthalides. These are compounds containing a 3-hydrocarbylidene-2-benzofuran-1(3H)-one moiety,.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Isocoumarans
Sub Class
Isobenzofuranones
Direct Parent
Phthalides
Alternative Parents
Anisoles / Medium-chain fatty acids / Alkyl aryl ethers / Methyl-branched fatty acids / Hydroxy fatty acids / Heterocyclic fatty acids / Unsaturated fatty acids / Dicarboxylic acids and derivatives / Vinylogous acids / Lactones
show 6 more
Substituents
Phthalide / Anisole / Medium-chain fatty acid / Alkyl aryl ether / Branched fatty acid / Methyl-branched fatty acid / Heterocyclic fatty acid / Hydroxy fatty acid / Dicarboxylic acid or derivatives / Fatty acyl
show 16 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
2-benzofurans, monocarboxylic acid, phenols, gamma-lactone (CHEBI:168396)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna binding
Specific Function
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore pl...
Gene Name
IMPDH1
Uniprot ID
P20839
Uniprot Name
Inosine-5'-monophosphate dehydrogenase 1
Molecular Weight
55405.365 Da
References
  1. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna binding
Specific Function
Catalyzes the conversion of inosine 5'-phosphate (IMP) to xanthosine 5'-phosphate (XMP), the first committed and rate-limiting step in the de novo synthesis of guanine nucleotides, and therefore pl...
Gene Name
IMPDH2
Uniprot ID
P12268
Uniprot Name
Inosine-5'-monophosphate dehydrogenase 2
Molecular Weight
55804.495 Da
References
  1. Vannozzi F, Filipponi F, Di Paolo A, Danesi R, Urbani L, Bocci G, Catalano G, De Simone P, Mosca F, Del Tacca M: An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc. 2004 Nov;36(9):2787-90. [PubMed:15621150]
  2. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, Hutchinson IV, Burckart GJ: A novel variant L263F in human inosine 5'-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics. 2007 Apr;17(4):283-90. [PubMed:17496727]
  3. Penuelas S, Noe V, Morales R, Ciudad CJ: Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH. Med Sci Monit. 2005 Jan;11(1):BR6-12. [PubMed:15614187]
  4. Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, Zaia JA, Yee JK: Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Mol Ther. 2006 Aug;14(2):236-44. Epub 2006 May 2. [PubMed:16647299]
  5. Dzidic A, Prgomet C, Mohr A, Meyer K, Bauer J, Meyer HH, Pfaffl MW: Effects of mycophenolic acid on inosine monophosphate dehydrogenase I and II mRNA expression in white blood cells and various tissues in sheep. J Vet Med A Physiol Pathol Clin Med. 2006 May;53(4):163-9. [PubMed:16629948]
  6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
  7. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165]
  2. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 2 lacks trans...
Gene Name
UGT1A9
Uniprot ID
O60656
Uniprot Name
UDP-glucuronosyltransferase 1-9
Molecular Weight
59940.495 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glucuronosyltransferase activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.Its unique specificity for 3,4-catechol estrogens and estriol su...
Gene Name
UGT2B7
Uniprot ID
P16662
Uniprot Name
UDP-glucuronosyltransferase 2B7
Molecular Weight
60694.12 Da
References
  1. Dostalek M, Court MH, Hazarika S, Akhlaghi F: Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos. 2011 Mar;39(3):448-55. doi: 10.1124/dmd.110.036608. Epub 2010 Dec 1. [PubMed:21123165]
  2. Picard N, Ratanasavanh D, Premaud A, Le Meur Y, Marquet P: Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism. Drug Metab Dispos. 2005 Jan;33(1):139-46. Epub 2004 Oct 6. [PubMed:15470161]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Retinoic acid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. Isoform 2 lacks transferase activity but acts as a negative reg...
Gene Name
UGT1A7
Uniprot ID
Q9HAW7
Uniprot Name
UDP-glucuronosyltransferase 1-7
Molecular Weight
59818.315 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Protein homodimerization activity
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform has specificity for phenols. Isoform 3 lacks trans...
Gene Name
UGT1A6
Uniprot ID
P19224
Uniprot Name
UDP-glucuronosyltransferase 1-6
Molecular Weight
60750.215 Da
References
  1. Miles KK, Kessler FK, Smith PC, Ritter JK: Characterization of rat intestinal microsomal UDP-glucuronosyltransferase activity toward mycophenolic acid. Drug Metab Dispos. 2006 Sep;34(9):1632-9. Epub 2006 Jun 21. [PubMed:16790558]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:47